Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. The agency is now heavily scrutinizing Phase 1 and 2 studies to see whether they identify the safest and most effective dose—while this change seems abrupt, it’s loomed over the field for a long time.
We’ve helped our clients adapt to the new standards with five best practices outlined in this article.
Related Insights
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Related Insights
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
Whitepaper
Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)
Sep 19, 2023
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023